Physician profile
Lucy A Wibbenmeyer
NPI 1346242906
$40,908.58
in general payments reported to CMS, 2019-2025
7 companies · $10K in 2025
The $10K reported for 2025 was more than what 96% of Surgical Critical Care providers received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,624 · 2020: $750 · 2023: $19K · 2024: $9,075 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K · Travel and Lodging: $2,330 · Food and Beverage: $1,554 · Honoraria: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,300.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,700.00 |
| Travel and Lodging | $2,330.29 |
| Food and Beverage | $1,554.20 |
| Honoraria | $650.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vericel Corporation | $30,757.19 | 2023-2025 | Nexobrid, Epicel (Cultured Epidermal Autografts) |
| Polynovo North America LLC | $7,254.79 | 2023-2024 | Novosorb Btm |
| Avita Medical Americas, LLC | $2,326.09 | 2019-2025 | Cohealyx, Recell, Permeaderm |
| Access Pro Medical, LLC | $271.42 | 2023 | Matriderm |
| Integra Lifesciences Corporation | $175.00 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Mallinckrodt Enterprises LLC | $124.09 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucy Wibbenmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.